antimiR-181c

antimiR-181c (also referred to as anti-miR-181c or miR-181c inhibitor) is a synthetic antisense oligonucleotide designed to target and inhibit microRNA-181c (specifically miR-181c-5p). Developed and investigated primarily in academic and research settings—including the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide—antimiR-181c is being studied for its therapeutic potential in diabetic vascular complications, ischemia, and wound healing. By silencing the anti-angiogenic miR-181c-5p, antimiR-181c relieves post-transcriptional repression of key pro-angiogenic and cell survival factors. This leads to the upregulation of vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor receptor 2 (VEGFR2), and B-cell lymphoma 2 (Bcl-2), alongside the activation of downstream ERK2 signaling. In preclinical models of diabetic hindlimb ischemia and wound healing, local administration of antimiR-181c has been shown to significantly enhance blood flow reperfusion, increase arteriolar and capillary density, and accelerate wound closure.

Other names

anti-miR-181canti-miR181canti-miR 181canti-miR-181c-5panti-miR181c-5panti-miR 181c-5pantimiR-181c-5pantimiR181c-5pantimiR 181c-5pmiR-181c inhibitormiR181c inhibitormiR 181c inhibitormicroRNA-181c inhibitormicroRNA181c inhibitormicroRNA 181c inhibitor